Arcus Biosciences, Inc.
RCUS· NYSE
Released Aug 8, 2024, after the close
10-Q filed Aug 8, 2024, 39 days after period end · 0001724521-24-000138
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $11.00M | $29.00M | $27.00M | $9.46M |
| Net Income | -$93.00M | -$75.00M | -$67.00M | -$75.97M |
| EPS Diluted |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| -$1.02 |
| -$1.04 |
| -$0.93 |
| -$1.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.